| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5700127 | Clinical Oncology | 2007 | 4 Pages |
Abstract
Our results showed similar responses and survival rates for patients with stage III or IV ovarian cancer treated with neoadjuvant platinum-based chemotherapy, when compared with patients who underwent primary suboptimal cytoreductive surgery. Our data therefore support the ongoing trials to determine the optimum timing of surgery for ovarian cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
D.D. Rosa, N.C. Ton, A. Clamp, S. Mullamitha, S. Lau, R. Clayton, H.C. Kitchener, J.H. Shanks, R. McVey, G.C. Jayson,